Urological Cancer Therapeutics Drugs Market 2027 By Type, Application | The Insight Partners

Urological Cancer Therapeutics Drugs Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Type (Xofigo (radium Ra 223 dichloride), Jevtana (cabazitaxel), Inlyta (axitinib), Votrient (pazopanib hydrochloride), Sutent (sunitinib malate), Zytiga (abiraterone acetate), Xtandi (enzalutamide), Opdivo (nivolumab), Provenge (sipuleucel-T)); Application (Hospital, Medical Research Laboratory, Others)

Report Code: TIPRE00011654 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
Covid
MARKET INTRODUCTION

Urological cancers are thought to account for 19.5% of global cancer prevalence, with kidney, prostate, testicular, and bladder cancer. However, the key indications covered in this report – accounting for the majority of that figure. Urological cancers affect the male and female urinary tract and the male reproductive organs. Prostate cancer is the most prevalent of these malignancies.

MARKET DYNAMICS

The urological cancer therapeutics drugs market is expected to grow due to the growing prevalence of chronic diseases and cancer. Moreover, the rise in government initiatives to enhance health care facilities and rising geriatric population propel the market growth in the forecast period.

MARKET SCOPE

The "Urological Cancer Therapeutics Drugs Market Analysis to 2027" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of urological cancer therapeutics drugs market with detailed market segmentation by type and application. The urological cancer therapeutics drugs market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in urological cancer therapeutics drugs market and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The urological cancer therapeutics drugs market is segmented on the basis of type and application. Based on type, the market is segmented as xofigo (radium ra 223 dichloride), jevtana (cabazitaxel), inlyta (axitinib), votrient (pazopanib hydrochloride), sutent (sunitinib malate), zytiga (abiraterone acetate), xtandi (enzalutamide), opdivo (nivolumab) and provenge (sipuleucel-T). On the basis of application, the market is categorized as hospital, medical research laboratory and others.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the urological cancer therapeutics drugs market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The urological cancer therapeutics drugs market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting urological cancer therapeutics drugs market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the urological cancer therapeutics drugs market in these regions.



Get more information on this report :

MARKET PLAYERS


The report covers key developments in the urological cancer therapeutics drugs market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from urological cancer therapeutics drugs market are anticipated to have lucrative growth opportunities in the future with the rising demand for urological cancer therapeutics drugs in the global market. Below mentioned is the list of few companies engaged in the urological cancer therapeutics drugs market.

The report also includes the profiles of key players in urological cancer therapeutics drugs market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.


  •   Abbott Laboratories
  •   AstraZeneca
  •   Bristol-Myers Squibb
  •   Dendreon Corporation
  •   GlaxoSmithKline plc
  •   Indevus Pharmaceuticals Inc
  •   Johnson and Johnson
  •   Novartis
  •   Pfizer
  •   Roche Healthcare
  •   Sanofi S.A.

The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.


Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Urological Cancer Therapeutics Drugs Market - By Type
1.3.2 Urological Cancer Therapeutics Drugs Market - By Application
1.3.3 Urological Cancer Therapeutics Drugs Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. UROLOGICAL CANCER THERAPEUTICS DRUGS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. UROLOGICAL CANCER THERAPEUTICS DRUGS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. UROLOGICAL CANCER THERAPEUTICS DRUGS MARKET - GLOBAL MARKET ANALYSIS
6.1. UROLOGICAL CANCER THERAPEUTICS DRUGS - GLOBAL MARKET OVERVIEW
6.2. UROLOGICAL CANCER THERAPEUTICS DRUGS - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. UROLOGICAL CANCER THERAPEUTICS DRUGS MARKET - REVENUE AND FORECASTS TO 2027 – TYPE
7.1. OVERVIEW
7.2. TYPE MARKET FORECASTS AND ANALYSIS
7.3. XOFIGO (RADIUM RA 223 DICHLORIDE)
7.3.1. Overview
7.3.2. Xofigo (radium Ra 223 dichloride) Market Forecast and Analysis
7.4. JEVTANA (CABAZITAXEL)
7.4.1. Overview
7.4.2. Jevtana (cabazitaxel) Market Forecast and Analysis
7.5. INLYTA (AXITINIB)
7.5.1. Overview
7.5.2. Inlyta (axitinib) Market Forecast and Analysis
7.6. VOTRIENT (PAZOPANIB HYDROCHLORIDE)
7.6.1. Overview
7.6.2. Votrient (pazopanib hydrochloride) Market Forecast and Analysis
7.7. SUTENT (SUNITINIB MALATE)
7.7.1. Overview
7.7.2. Sutent (sunitinib malate) Market Forecast and Analysis
7.8. ZYTIGA (ABIRATERONE ACETATE)
7.8.1. Overview
7.8.2. Zytiga (abiraterone acetate) Market Forecast and Analysis
7.9. XTANDI (ENZALUTAMIDE)
7.9.1. Overview
7.9.2. Xtandi (enzalutamide) Market Forecast and Analysis
7.10. OPDIVO (NIVOLUMAB)
7.10.1. Overview
7.10.2. Opdivo (nivolumab) Market Forecast and Analysis
7.11. PROVENGE (SIPULEUCEL-T)
7.11.1. Overview
7.11.2. Provenge (sipuleucel-T) Market Forecast and Analysis
8. UROLOGICAL CANCER THERAPEUTICS DRUGS MARKET - REVENUE AND FORECASTS TO 2027 – APPLICATION
8.1. OVERVIEW
8.2. APPLICATION MARKET FORECASTS AND ANALYSIS
8.3. HOSPITAL
8.3.1. Overview
8.3.2. Hospital Market Forecast and Analysis
8.4. MEDICAL RESEARCH LABORATORY
8.4.1. Overview
8.4.2. Medical Research Laboratory Market Forecast and Analysis
8.5. OTHERS
8.5.1. Overview
8.5.2. Others Market Forecast and Analysis
9. UROLOGICAL CANCER THERAPEUTICS DRUGS MARKET REVENUE AND FORECASTS TO 2027 – GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Urological Cancer Therapeutics Drugs Market Overview
9.1.2 North America Urological Cancer Therapeutics Drugs Market Forecasts and Analysis
9.1.3 North America Urological Cancer Therapeutics Drugs Market Forecasts and Analysis - By Type
9.1.4 North America Urological Cancer Therapeutics Drugs Market Forecasts and Analysis - By Application
9.1.5 North America Urological Cancer Therapeutics Drugs Market Forecasts and Analysis - By Countries
9.1.5.1 United States Urological Cancer Therapeutics Drugs Market
9.1.5.1.1 United States Urological Cancer Therapeutics Drugs Market by Type
9.1.5.1.2 United States Urological Cancer Therapeutics Drugs Market by Application
9.1.5.2 Canada Urological Cancer Therapeutics Drugs Market
9.1.5.2.1 Canada Urological Cancer Therapeutics Drugs Market by Type
9.1.5.2.2 Canada Urological Cancer Therapeutics Drugs Market by Application
9.1.5.3 Mexico Urological Cancer Therapeutics Drugs Market
9.1.5.3.1 Mexico Urological Cancer Therapeutics Drugs Market by Type
9.1.5.3.2 Mexico Urological Cancer Therapeutics Drugs Market by Application
9.2. EUROPE
9.2.1 Europe Urological Cancer Therapeutics Drugs Market Overview
9.2.2 Europe Urological Cancer Therapeutics Drugs Market Forecasts and Analysis
9.2.3 Europe Urological Cancer Therapeutics Drugs Market Forecasts and Analysis - By Type
9.2.4 Europe Urological Cancer Therapeutics Drugs Market Forecasts and Analysis - By Application
9.2.5 Europe Urological Cancer Therapeutics Drugs Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Urological Cancer Therapeutics Drugs Market
9.2.5.1.1 Germany Urological Cancer Therapeutics Drugs Market by Type
9.2.5.1.2 Germany Urological Cancer Therapeutics Drugs Market by Application
9.2.5.2 France Urological Cancer Therapeutics Drugs Market
9.2.5.2.1 France Urological Cancer Therapeutics Drugs Market by Type
9.2.5.2.2 France Urological Cancer Therapeutics Drugs Market by Application
9.2.5.3 Italy Urological Cancer Therapeutics Drugs Market
9.2.5.3.1 Italy Urological Cancer Therapeutics Drugs Market by Type
9.2.5.3.2 Italy Urological Cancer Therapeutics Drugs Market by Application
9.2.5.4 Spain Urological Cancer Therapeutics Drugs Market
9.2.5.4.1 Spain Urological Cancer Therapeutics Drugs Market by Type
9.2.5.4.2 Spain Urological Cancer Therapeutics Drugs Market by Application
9.2.5.5 United Kingdom Urological Cancer Therapeutics Drugs Market
9.2.5.5.1 United Kingdom Urological Cancer Therapeutics Drugs Market by Type
9.2.5.5.2 United Kingdom Urological Cancer Therapeutics Drugs Market by Application
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Urological Cancer Therapeutics Drugs Market Overview
9.3.2 Asia-Pacific Urological Cancer Therapeutics Drugs Market Forecasts and Analysis
9.3.3 Asia-Pacific Urological Cancer Therapeutics Drugs Market Forecasts and Analysis - By Type
9.3.4 Asia-Pacific Urological Cancer Therapeutics Drugs Market Forecasts and Analysis - By Application
9.3.5 Asia-Pacific Urological Cancer Therapeutics Drugs Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Urological Cancer Therapeutics Drugs Market
9.3.5.1.1 Australia Urological Cancer Therapeutics Drugs Market by Type
9.3.5.1.2 Australia Urological Cancer Therapeutics Drugs Market by Application
9.3.5.2 China Urological Cancer Therapeutics Drugs Market
9.3.5.2.1 China Urological Cancer Therapeutics Drugs Market by Type
9.3.5.2.2 China Urological Cancer Therapeutics Drugs Market by Application
9.3.5.3 India Urological Cancer Therapeutics Drugs Market
9.3.5.3.1 India Urological Cancer Therapeutics Drugs Market by Type
9.3.5.3.2 India Urological Cancer Therapeutics Drugs Market by Application
9.3.5.4 Japan Urological Cancer Therapeutics Drugs Market
9.3.5.4.1 Japan Urological Cancer Therapeutics Drugs Market by Type
9.3.5.4.2 Japan Urological Cancer Therapeutics Drugs Market by Application
9.3.5.5 South Korea Urological Cancer Therapeutics Drugs Market
9.3.5.5.1 South Korea Urological Cancer Therapeutics Drugs Market by Type
9.3.5.5.2 South Korea Urological Cancer Therapeutics Drugs Market by Application
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Urological Cancer Therapeutics Drugs Market Overview
9.4.2 Middle East and Africa Urological Cancer Therapeutics Drugs Market Forecasts and Analysis
9.4.3 Middle East and Africa Urological Cancer Therapeutics Drugs Market Forecasts and Analysis - By Type
9.4.4 Middle East and Africa Urological Cancer Therapeutics Drugs Market Forecasts and Analysis - By Application
9.4.5 Middle East and Africa Urological Cancer Therapeutics Drugs Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Urological Cancer Therapeutics Drugs Market
9.4.5.1.1 South Africa Urological Cancer Therapeutics Drugs Market by Type
9.4.5.1.2 South Africa Urological Cancer Therapeutics Drugs Market by Application
9.4.5.2 Saudi Arabia Urological Cancer Therapeutics Drugs Market
9.4.5.2.1 Saudi Arabia Urological Cancer Therapeutics Drugs Market by Type
9.4.5.2.2 Saudi Arabia Urological Cancer Therapeutics Drugs Market by Application
9.4.5.3 U.A.E Urological Cancer Therapeutics Drugs Market
9.4.5.3.1 U.A.E Urological Cancer Therapeutics Drugs Market by Type
9.4.5.3.2 U.A.E Urological Cancer Therapeutics Drugs Market by Application
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Urological Cancer Therapeutics Drugs Market Overview
9.5.2 South and Central America Urological Cancer Therapeutics Drugs Market Forecasts and Analysis
9.5.3 South and Central America Urological Cancer Therapeutics Drugs Market Forecasts and Analysis - By Type
9.5.4 South and Central America Urological Cancer Therapeutics Drugs Market Forecasts and Analysis - By Application
9.5.5 South and Central America Urological Cancer Therapeutics Drugs Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Urological Cancer Therapeutics Drugs Market
9.5.5.1.1 Brazil Urological Cancer Therapeutics Drugs Market by Type
9.5.5.1.2 Brazil Urological Cancer Therapeutics Drugs Market by Application
9.5.5.2 Argentina Urological Cancer Therapeutics Drugs Market
9.5.5.2.1 Argentina Urological Cancer Therapeutics Drugs Market by Type
9.5.5.2.2 Argentina Urological Cancer Therapeutics Drugs Market by Application
10. IMPACT OF COVID-19 PANDEMIC ON GLOBAL UROLOGICAL CANCER THERAPEUTICS DRUGS MARKET
10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 Rest of the World
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. UROLOGICAL CANCER THERAPEUTICS DRUGS MARKET, KEY COMPANY PROFILES
12.1. ABBOTT LABORATORIES
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. ASTRAZENECA
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. BRISTOL-MYERS SQUIBB
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. DENDREON CORPORATION
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. GLAXOSMITHKLINE PLC
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. INDEVUS PHARMACEUTICALS INC
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. JOHNSON AND JOHNSON
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. NOVARTIS
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. PFIZER
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. ROCHE HEALTHCARE
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
12.11. SANOFI S.A.
12.11.1. Key Facts
12.11.2. Business Description
12.11.3. Products and Services
12.11.4. Financial Overview
12.11.5. SWOT Analysis
12.11.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
The List of Companies

1. Abbott Laboratories
2. AstraZeneca
3. Bristol-Myers Squibb
4. Dendreon Corporation
5. GlaxoSmithKline plc
6. Indevus Pharmaceuticals Inc
7. Johnson and Johnson
8. Novartis
9. Pfizer
10. Roche Healthcare
11. Sanofi S.A.
TIPRE00011654
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking